abiraterone has been researched along with Cancer of Prostate in 342 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.29) | 18.2507 |
| 2000's | 20 (5.85) | 29.6817 |
| 2010's | 253 (73.98) | 24.3611 |
| 2020's | 68 (19.88) | 2.80 |
| Authors | Studies |
|---|---|
| Barrie, SE; Jarman, M; Potter, GA; Rowlands, MG | 1 |
| Brodie, AM; Clement, OO; Freeman, CM; Handratta, VD; Hartmann, RW; Njar, VC; Vasaitis, TS | 1 |
| Brodie, AM; Chopra, P; Farquhar, R; Gediya, LK; Guo, Z; Handratta, VD; Kataria, R; Newman, D; Njar, VC; Qiu, Y; Vasaitis, TS | 1 |
| Hartmann, RW; Jagusch, C; Lauterbach, T; Müller-Vieira, U; Negri, M; Pinto-Bazurco Mendieta, MA | 1 |
| Hartmann, RW; Hille, UE; Hu, Q; Jagusch, C; Yin, L | 1 |
| Hartmann, RW; Haupenthal, J; Hille, UE; Hu, Q; Jagusch, C | 1 |
| Engel, M; Hartmann, RW; Hu, Q; Pinto-Bazurco Mendieta, MA | 1 |
| Ajduković, JJ; Celić, AS; Djurendić, EA; Gaši, KM; Jakimov, DS; Klisurić, OR; Petri, ET; Sakač, MN | 1 |
| Brodie, AM; Njar, VC | 1 |
| Chen, F; Fang, Y; Gu, S; Sun, X; Wang, M; Zhu, J; Zhu, Z | 1 |
| Chen, IC; Chen, MC; Hsieh, CM; Hsu, KC; Lai, RW; Lin, TE; Liou, JP; Nepali, K; Ojha, R; Pan, SL | 1 |
| Attard, G; Birtle, A; Brawley, CD; Chowdhury, S; Clarke, NW; Cook, AD; Dearnaley, DP; Fackrell, D; Gale, J; Gilbert, DC; Gillessen, S; Gray, E; Hoskin, P; James, ND; Jones, RJ; Langley, RE; Macnair, A; Malik, ZI; Matheson, D; McPhail, N; Millman, R; Morgans, AK; Murphy, L; O'Sullivan, JM; Parker, CC; Parmar, MKB; Perna, C; Protheroe, A; Pugh, C; Rudman, S; Rush, HL; Russell, JM; Sydes, MR; Tanguay, JS; Tolan, S; Vengalil, S; Wagstaff, J | 1 |
| Ito, T; Koie, T; Miyake, H; Naiki, T; Nakane, K; Shiroki, R; Sugiyama, Y; Takahara, K; Yasui, T | 1 |
| Fallara, G; Franck Lissbrant, I; Garmo, H; Gedeborg, R; Stattin, P; Styrke, J; Thellenberg-Karlsson, C | 1 |
| Armstrong, AJ; Dzimitrowicz, HE | 1 |
| Chiba, S; Egawa, S; Habuchi, T; Hata, K; Hatakeyama, S; Horikawa, Y; Ishida, T; Kashima, S; Kimura, T; Koizumi, A; Kumazawa, T; Maita, S; Narita, S; Nomura, K; Ohyama, C; Okane, K; Sato, H; Shimoda, J; Suzuki, T; Takayama, K; Yamamoto, R; Yanagisawa, T | 1 |
| Abadie-Lacourtoisie, S; Berdah, JF; Berthold, D; Bossi, A; Calabro, F; Carles, J; Chand-Fouche, ME; El Kouri, C; Escande, A; Fizazi, K; Fléchon, A; Foulon, S; Freixa, SV; Gravis, G; Hasbini, A; Jamaluddin, M; Kacso, G; Laguerre, B; Latorzeff, I; Magne, N; Martin, E; McDermott, R; Mourey, L; Priou, F; Rieger, I; Ronchin, P; Rosello, A; Roubaud, G; Schlurmann, F; Silva, M; Supiot, S; Thiery-Vuillemin, A; Tombal, B | 1 |
| Keating, NL | 1 |
| Caram, MEV; Hollenbeck, BK; Kaufman, SR; Lai, LY; Maganty, A; Oerline, MK; Shahinian, VB | 1 |
| Filippova, TA; Kuzikov, AV; Masamrekh, RA; Sherbakov, KA; Shumyantseva, VV; Veselovsky, AV | 1 |
| Baker, A; Khalid, M; Khan, MS; Uddin, I | 1 |
| Basu, A; Carlson, JJ; Garrison, LP; Jiao, B; Nyame, YA | 1 |
| Habuchi, T; Hamaya, T; Hashimoto, Y; Hata, K; Hatakeyama, S; Kimura, T; Narita, S; Ohyama, C; Okamoto, T; Ozaki, K; Tanaka, T; Togashi, K; Yamamoto, H; Yanagisawa, T; Yoneyama, T | 1 |
| Enei, Y; Fukuokaya, W; Habuchi, T; Hara, S; Hata, K; Hatakeyama, S; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Nakazono, M; Narita, S; Ohyama, C; Otsuka, T; Sano, T; Shariat, SF; Yanagisawa, T; Yata, Y | 1 |
| Auchus, RJ; Bart, AG; Peng, HM; Petrunak, EM; Scott, EE | 1 |
| Dou, T; Gao, L; Lai, KP; Li, J; Li, R; Li, X; Li, Z; Lin, X; Liu, J; Xu, H | 1 |
| Buck, SAJ; de Bruijn, P; de Wit, R; Ghobadi-Moghaddam-Helmantel, IM; Koolen, SLW; Lam, MH; Mathijssen, RHJ | 1 |
| Antonarakis, ES; Arafa, AT; Blader, LR; Engle, J; Jha, G; Ramakrishna, K; Ryan, CJ; Zorko, NA | 1 |
| Berlin, D; Chin, JLK; Fernandes, R; Finelli, A; Fleshner, NE; Hamilton, RJ; Hansen, AR; Herrera-Caceres, JO; Hersey, K; Joshua, AM; Kenk, M; Kulkarni, GS; Lajkosz, K; Moussa, M; Sayyid, RK; Sridhar, S; Sweet, J; van der Kwast, T; Veloso, R; Winquist, E; Zlotta, AR | 1 |
| Detlefsen, AJ; Duan, L; Mesaros, CA; Penning, TM | 1 |
| Baloch, HM; Grice-Patil, ZJ; Hoang, TD; Mai, VQ; Selig, DJ; Shakir, MK | 1 |
| Beck, JR; Correa, AF; Geynisman, DM; Handorf, EA; Ramamurthy, C | 1 |
| Aebersold, DM; Ali, A; Attard, G; Brawley, CD; Chowdhury, S; Clarke, NW; Cook, A; Cross, WR; de Bono, JS; Dearnaley, DP; Douis, H; Gillessen, S; Gilson, C; Hoyle, AP; Ingleby, F; James, ND; Jones, RJ; Mason, MD; Matheson, D; Millman, R; Parker, CC; Parmar, MKB; Ritchie, AWS; Russell, M; Sydes, MR | 1 |
| Aghaee-Bakhtiari, SH; Jalili, A; Mahjoubin Tehran, M; Rezaei, S; Sahebkar, A | 1 |
| Nakata, W; Nin, M; Tsujihata, M; Tsujimoto, Y; Tsujimura, G; Yamamichi, G | 1 |
| Bretagne, M; Dureau, P; Funck-Brentano, C; Lebrun-Vignes, B; Malouf, GG; Moslehi, JJ; Pariente, A; Potey, C; Roden, DM; Salem, JE; Shaffer, CM | 1 |
| Baldassarri, V; Bracarda, S; De Nunzio, C; Iacovelli, R; Lombardo, R; Nacchia, A; Sica, A; Tema, G; Tubaro, A; Voglino, O | 1 |
| Autorino, R; Castellan, P; Cindolo, L; Di Nicola, M; Marchioni, M; Novara, G; Paul, AK; Primiceri, G; Schips, L; Veccia, A | 1 |
| Condon, B; Liskaser, G; Murphy, DG; Thangasamy, IA | 1 |
| Bergh, A; Brattsand, M; Josefsson, A; Lundholm, M; Thellenberg-Karlsson, C; Thysell, E; Widmark, A; Wikström, P; Ylitalo, EB | 1 |
| Antonarakis, ES; Eisenberger, MA | 3 |
| Taneja, SS | 4 |
| Beriwal, S; Rodríguez-López, JL | 1 |
| Hu, X; Liu, L; Pang, L; Wang, W; Xu, B; Yang, H; Zhang, X | 1 |
| Ardizzoni, A; Battelli, N; Conti, A; Di Nunno, V; Massari, F; Mollica, V; Montironi, R; Santoni, M | 1 |
| Rubio-Briones, J | 1 |
| Alyamani, M; Auchus, RJ; O'Day, P; Sharifi, N; Wright, C | 1 |
| Chan, KKW; Everest, L; Jiang, DM; Saluja, R; Sridhar, SS; Wong, SE | 1 |
| Cookson, MS; Parker, DC | 1 |
| Batra, A; Bhethanabhotla, S; Biswas, B; Das, CK; Gupta, VG; Mahindru, S; Mehta, P; Patel, A; Pramanik, R; Srivastava, P; Tannock, IF; Tilak, T | 1 |
| Egawa, S; Mori, K; Shariat, SF | 1 |
| Di Nunno, V; Massari, F; Mollica, V | 1 |
| Fusaro, M; Kubiszewski, M; Leś, A; Menaszek, E; Sidoryk, K; Stolarczyk, EU; Stolarczyk, K; Strzempek, W; Łaszcz, M | 1 |
| O'Reilly, S; Peters, N; Zameer, MZ | 1 |
| Baston, C; Gingu, C; Guler-Margaritis, SS; Preda, A; Sinescu, I | 1 |
| Gupta, A; Premnath, N; Sedhom, R | 1 |
| Chang, EM; Deville, C; Feng, FY; Kishan, AU; Koontz, BF; Nickols, NG; Ost, P; Parikh, NR; Phillips, R; Raldow, AC; Reiter, RE; Rettig, MB; Spratt, DE; Steinberg, ML; Tran, PT; Vapiwala, N | 1 |
| Chai, CLL; Chan, ECY; Cheong, EJY; Chiong, E; Esuvaranathan, K; Fan, H; Figg, WD; Lin, F; Miners, JO; Nair, PC; Neo, RWY; Peer, CJ; Szmulewitz, RZ; Tu, HT | 1 |
| Hamilou, Z | 1 |
| Griebling, TL | 1 |
| Alongi, F; Arcangeli, S; Borghesi, S; Fersino, S; Jereczek-Fossa, BA; Magrini, SM; Mortellaro, G | 1 |
| Caram, MEV; Dusetzina, S; Herrel, LA; Hollenbeck, BK; Kaufman, SR; Modi, PK; Oerline, MK; Shahinian, V; Skolarus, TA | 1 |
| Armstrong, CM; D'Abronzo, LS; Evans, CP; Gao, AC; Li, PK; Liu, C; Liu, L; Lombard, AP; Lou, W; Ning, S; Yang, JC; Zhao, J; Zhao, R | 1 |
| Fontana, F; Limonta, P; Marzagalli, M; Montagnani Marelli, M; Moretti, RM; Raimondi, M | 1 |
| Dillenburg Weiss, TL; Gasparin Verza, S; Gössling, G; Linden, R; Schwartsmann, G; Venzon Antunes, M | 1 |
| Avcı, S; Kırca, M; Ozpolat, B; Soylu, H; Ustunel, I | 1 |
| Berchuck, J; Bubley, GJ; Chang, PK; Kibel, AS; Kwak, L; McKay, RR; Silver, R; Taplin, ME; Wagner, A; Xie, W; Zhang, Z | 1 |
| Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK | 1 |
| Batter, S; Frank, RC; Kaplan, F; Kazanjian, M; Levy, G; Martignetti, J; Martino, C; Pandya, D; Shah, M | 1 |
| Arranz, JA; Castro, E; Climent, MA; Gallardo, E; González Del Alba, A; Gonzalez-Billalabeitia, E; Lorente, D; Maroto, JP; Méndez-Vidal, MJ; Vazquez, S | 1 |
| Bundschuh, RA; Dolscheid-Pommerich, RC; Essler, M; Kristiansen, G; Kürpig, S; Mathy, CS; Mayr, T; Meisenheimer, M; Muders, MH; Stoffel-Wagner, B | 1 |
| Boukovala, M; Brössner, C; Efstathiou, E; Gustafsson, JA; Spetsieris, N; Wang, L; Warner, M; Wu, WF | 1 |
| Addison, D; Baliga, R; Calaway, AC; Campbell, CM; Challa, AA; Cullen, J; Desai, N; Deswal, A; Garcia, J; Guha, A; Kutty, S; Vallakati, A; Weintraub, NL | 1 |
| Addison, D; Baumann, BC; Calaway, AC; Campbell, CM; Cullen, J; Desai, NR; Fradley, MG; Garcia, JA; Ghosh, AK; Guha, A; Lenihan, DJ; Ponsky, L; Reimers, MA; Weintraub, N; Zhang, KW | 1 |
| Buck, SAJ; de Wit, R; Robbrecht, DGJ | 1 |
| Barbier, RH; Chau, CH; Figg, WD; Lee, KY; McCrea, EM; Price, DK; Risdon, EN; Strope, JD | 1 |
| Bilen, MA; Brown, JT; Carthon, B; Caulfield, S; Kucuk, O; Lafollette, J; Liu, Y; Moore, M; Nazha, B; Russler, G; Smith, KER; Wan, L; Yantorni, L | 1 |
| Armstrong, AJ; Bubley, G; Chen, XE; Choueiri, TK; Dehm, SM; Emamekhoo, H; Feng, FY; Gilsdorf, CS; Halabi, S; Kwak, L; Lang, JM; McKay, RR; Morris, MJ; Rathkopf, D; Scher, HI; Silver, R; Singh, A; Sperger, JM; Stahlfeld, CN; Taplin, ME; Wei, XX; Wolfe, SK; Wyatt, AW; Zhang, Z; Zhao, SG | 1 |
| Chapman, JG; Guengerich, FP; McCarty, KD; Tateishi, Y | 1 |
| Chen, J; Chen, N; Chen, X; Dai, J; He, B; Liang, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Tao, R; Wang, Z; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhu, S; Zhu, X | 1 |
| Herrera Imbroda, B; Sáez Barranquero, F | 1 |
| Brower, V | 1 |
| Saad, F; Traboulsi, SL | 1 |
| Fidan, E; Fidan, S; Kocak, G | 1 |
| Tombal, B; van Soest, RJ | 1 |
| Gschwend, J; Miller, K; Ohlmann, CH | 1 |
| Lee, BH | 1 |
| Bedussi, F; Berruti, A; Dalla Volta, A; Ferrari, V; Fragni, M; Galli, D; Lazzari, B; Memo, M; Roca, E; Rossini, E; Sigala, S; Valcamonico, F; Vezzoli, S | 1 |
| Black, PC; Struss, WJ | 1 |
| Boccardo, F; Messina, C; Messina, M | 1 |
| Agarwal, N; Hahn, AW; Hale, P; Rathi, N | 1 |
| Baka, A; de Meijer, C; Gaultney, JG; Leliveld-Kors, AM; Noordzij, W; Peters, ML; van den Berg, PH; van den Bosch, J; Wyndaele, D | 1 |
| Allegretta, G; de Mello Martins, AGG; Eberhard, J; Hartmann, RW; Haupenthal, J; Hoffmann, M; Junker, K; Müller, R; Ohlmann, CH; Stöckle, M; Unteregger, G; van der Zee, JA | 1 |
| Bernhardt, R; Brixius-Anderko, S; Dick, B; Malikova, J; Pandey, AV; Parween, S; Udhane, SS | 1 |
| James, ND; Spears, MR; Sydes, MR | 2 |
| Penel, N | 2 |
| de Bono, J; Eisenberger, M; Sartor, O | 1 |
| Tannock, IF | 1 |
| Guessous, F; Ismaili, N | 1 |
| Chi, KN; Fizazi, K | 1 |
| De Bono, J; Sumanasuriya, S | 1 |
| Aggarwal, R | 1 |
| Culig, Z; Eder, I; Eigentler, A; Handle, F; Heidegger, I; Hoefer, J; Klocker, H; Kroon, J; Leo, A; Ploner, C; Puhr, M; Schaefer, G; Van der Pluijm, G | 1 |
| Brown, JS; Cunningham, JJ; Gatenby, RA; Zhang, J | 1 |
| Figg, WD; Madan, RA; Schmidt, KT | 1 |
| Antonarakis, ES; Armstrong, AJ; McNamara, M; Sweeney, C | 1 |
| Atkins, KM; Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, M; Renshaw, AA; Small, EJ; Wu, J | 1 |
| Abrahamsson, M; Falkenius, J; Henriksson, R; Lindquist, M; Lööv, SÅ; Norin, S; Öhman, D | 1 |
| Carl, CO; Petersen, C; Schwarz, R | 1 |
| Artibani, W; Bimbatti, D; Bria, E; Brunelli, M; Ciccarese, C; Fantinel, E; Iacovelli, R; Mazzarotto, R; Muraglia, A; Porcaro, AB; Romano, M; Siracusano, S; Tortora, G | 1 |
| Annala, M; Azad, AA; Beja, K; Chi, KN; Eigl, BJ; Finch, D; Gleave, ME; Khalaf, D; Kollmannsberger, C; Nykter, M; Oja, CD; Sunderland, K; Taavitsainen, S; Vandekerkhove, G; Vergidis, J; Warner, EW; Wyatt, AW; Zulfiqar, M | 1 |
| Folkvaljon, Y; Franck Lissbrant, I; Hjälm-Eriksson, M; Lambe, M; Robinson, D; Stattin, P; Törnblom, M; Ventimiglia, E | 1 |
| de Bono, JS; Sartor, O | 1 |
| Drakaki, A; Faiena, I; Pantuck, AJ; Salmasi, A | 1 |
| Chen, J; Dai, Y; Gao, Q | 1 |
| Butler, LM; Centenera, MM; Ebrahimie, E; Selth, LA; Tilley, WD | 1 |
| Burdett, S; Parmar, MKB; Rydzewska, LHM; Tierney, JF; Vale, CL | 1 |
| Gourdin, T | 2 |
| Klaassen, Z; Wallis, CJD | 1 |
| Bangs, R; Basch, E; Celano, P; Hotte, SJ; Loblaw, A; Milowsky, MI; Morris, MJ; Rathkopf, D; Rumble, RB | 1 |
| Efstathiou, E | 1 |
| Corey, E; Lam, HM; Nguyen, HM | 1 |
| Aguiar, P; Haaland, B; Lopes, G; Tan, PS | 1 |
| Almassi, N; Alyamani, M; Auchus, RJ; Berk, MP; Chien, C; Emamekhoo, H; Figg, WD; Garcia, J; Grivas, P; Hu, B; Hwang, TH; Koshkin, VS; Mendiratta, P; Park, S; Peer, CJ; Rini, B; Sharifi, N; Taylor, J; Tyler, A; Upadhyay, S | 1 |
| Fizazi, K; Hamilou, Z; Saad, F | 1 |
| Crabb, SJ | 1 |
| Akaza, H; Buchan, NC; Chiong, E; Chung, BH; Davis, ID; Kanesvaran, R; Khochikar, M; Le Chuyen, V; Letran, J; Lojanapiwat, B; Murphy, DG; Ng, CF; Ong, T; Pu, YS; Saad, M; Schubach, K; Türkeri, L; Umbas, R; Williams, S; Ye, DW | 1 |
| Saad, F | 2 |
| Pachynski, RK; Xu, L | 1 |
| Aggarwal, R; Behrens, CR; Bidlingmaier, S; Burlingame, AL; Hann, BC; Lee, NK; Liu, B; Liu, Y; Paris, PL; Premasekharan, G; Seo, Y; Sherbenou, DW; Shuman, MA; Simko, JP; Small, EJ; Su, Y | 1 |
| Ferroni, C; Varchi, G | 1 |
| Brown, JS; Cunningham, JJ; Gatenby, RA; Staňková, K | 1 |
| Bolognini, C; Gassian, N; Klajer, E; Loriot, Y; Meynard, G; Thiery-Vuillemin, A | 1 |
| Hu, J; Shen, H; Song, D; Sun, Z; Wang, Y; Wen, X; Xu, S; Xu, Y; Zhang, J | 1 |
| Armstrong, CM; Chen, HW; Dall'Era, M; Evans, CP; Gao, AC; Liu, C; Liu, L; Lombard, AP; Lou, W; Noel, ODV; Tepper, CG; Yang, JC; Zhao, R | 1 |
| Eto, M; Inokuchi, J; Kobayashi, T; Namitome, R; Shiota, M; Tatsugami, K | 1 |
| Kretschmer, A; Todenhöfer, T | 1 |
| Caron, P; Guillemette, C; Lévesque, E; Turcotte, V | 1 |
| Halabi, S; Parelukar, WR; Rydzewska, L; Tierney, JF; Vale, CL | 1 |
| Buonerba, C; Di Lorenzo, G; Fizazi, K; Pagliuca, M | 1 |
| Feng, FY; Fizazi, K; Vicier, C | 1 |
| Akamatsu, S; Eto, M; Fujimoto, N; Fujiwara, M; Habuchi, T; Narita, S; Ogawa, O; Shiota, M; Sumiyoshi, T; Uchiumi, T | 1 |
| James, ND | 1 |
| Bubley, GJ; Calagua, C; Chang, P; Chang, SL; Ellis, WJ; Harshman, LC; Kibel, AS; Lin, DW; Lis, R; McKay, RR; Montgomery, B; Pienta, KJ; Ross, AE; Taplin, ME; Trinh, QD; Wagner, AA; Xie, W; Ye, H; Zhang, Z | 1 |
| Aguiar, PN; Barreto, CMN; Giglio, AD; Gutierres, BS; Lopes, GL; Simko, S; Tan, PS | 1 |
| Miller, K | 2 |
| Chen, RC; Choudhury, A; Henry, A; Mistry, H; Mitin, T; Pinkawa, M; Spratt, DE | 1 |
| Duttagupta, P; Hsu, J; Jones, J; Kortylewski, M; Lucia, M; Moreira, D; Pal, SK; White, SW; Won, H | 1 |
| Battaglia, A; De Meerleer, G; Devos, G; Everaerts, W; Joniau, S; Moris, L; Tosco, L; Van den Broeck, T | 1 |
| Berghen, C; De Meerleer, G; Devos, G; Joniau, S | 1 |
| Bedussi, F; Berruti, A; Buttigliero, C; Dalla Volta, A; Ferrari, L; Pia, A; Roca, E; Sigala, S; Tucci, M; Vittorio Scagliotti, G | 1 |
| Eto, M; Imada, K; Inokuchi, J; Kajioka, S; Kashiwagi, E; Shiota, M; Takeuchi, A; Tatsugami, K; Ushijima, M | 1 |
| Hammerer, P; Manka, L | 1 |
| Chouahnia, K; Culine, S; Fossey-Diaz, V; Guetz, GD; Landre, T; Taleb, C | 1 |
| Chapin, BF; Ranasinghe, WKB; Reichard, CA | 1 |
| Atenafu, E; Duong, BTV; Green, BJ; Hansen, AR; Joshua, AM; Kelley, SO; Labib, M; Mohamadi, RM; Nguyen, V; Thiagalingam, P; Weeber, P | 1 |
| Burchardt, M; Daragan, G; Hoffmann, J; Kraus, T; Mustea, A; Stope, MB; Vasko, T; Ziegler, P | 1 |
| Agarwal, N; Pal, SK; Swami, U | 1 |
| Chang, KS; Ezzell, EE; George, BJ | 1 |
| Gennigens, C; Sautois, B | 1 |
| Burki, TK | 1 |
| Ashworth, A; Assiotis, I; Attard, G; Barber, LJ; Campbell, J; Chen, L; de Bono, J; Fenwick, K; Fong, P; Gevensleben, H; Hylands, L; Kaye, S; Koh, D; Kozarewa, I; Lord, CJ; Miranda, S; Molife, LR; Olmos, D; Omlin, A; Reid, AH; Riisnaes, R; Sandhu, SK; Tunariu, N; Yap, TA | 1 |
| Monneret, C | 1 |
| Albiges, L; Attard, G; Bianchini, D; De Bono, JS; Fizazi, K; Ileana, E; Loriot, Y; Massard, C; Patrikidou, A; Pezaro, C; Sandhu, S | 1 |
| Arlt, W; Attard, G; Berruti, A; Bironzo, P; Pia, A; Scagliotti, G; Terzolo, M; Tucci, M; Vignani, F | 1 |
| Armstrong, AJ; Bitting, RL; Chi, KN; Ellard, SL; Noonan, KL; North, S | 1 |
| Chen, HL; Du, JJ; Li, YC | 1 |
| Kolesar, J; Simondsen, K | 1 |
| Nishiyama, T | 1 |
| Kellokumpu-Lehtinen, P; Tammela, T | 1 |
| Aparicio, AM; Goldkorn, A; Quinn, DI | 1 |
| Attard, G; Bianchini, D; Cassidy, AM; de Bono, JS; Mukherji, D; Olmos, D; Omlin, A; Pezaro, C; Reid, AH; Seed, G; Tunariu, N | 1 |
| Hartmann, RW; Hu, Q; Yin, L | 1 |
| Arlen, PM; Madan, RA | 2 |
| Brossard, D; Dallemagne, P; Duterque-Coquillaud, M; El Kihel, L; Galera, P; Haider, SM; Khalid, M; Legay, R; Moslemi, S; Rault, S; Sgobba, M; Zhang, Y | 1 |
| Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Mukherji, D; Omlin, A; Parker, C; Pezaro, CJ; Sandhu, S; Van As, N; Zaidi, S | 1 |
| Berg, KD; Brasso, K; Iversen, P; Røder, MA; Thomsen, FB | 1 |
| Dehm, SM; Hwang, TH; Li, Y; Manlove, LS; Nyquist, MD; Silverstein, KA; Vessella, RL; Voytas, DF | 1 |
| Hu, Q; Yin, L | 1 |
| D'Amico, AV | 1 |
| Balk, SP; Cai, C; Chen, S; Mostaghel, EA; Nelson, PS; Sowalsky, AG; Voznesensky, OS; Yu, Z | 1 |
| Caro Teller, JM; Cortijo Cascajares, S; Escribano Valenciano, I; Ferrari Piquero, JM; Serrano Garrote, O | 1 |
| Amadori, D; Bianchi, E; Burgio, SL; Carretta, E; Conteduca, V; De Giorgi, U; Fabbri, F; Kopf, B; Menna, C; Rossi, L | 1 |
| Labrie, F | 1 |
| Aebersold, D; Attard, G; Cassoly, E; Clarke, NW; de Bono, JS; Dearnaley, DP; James, ND; Mason, MD; Matheson, D; Millman, R; Parker, CC; Parmar, MK; Ritchie, AW; Russell, JM; Schiavone, F; Spears, MR; Sydes, MR; Thalmann, G | 1 |
| Antonarakis, ES; Luo, J; Nakazawa, M | 1 |
| O'Dowd, A | 1 |
| Gartrell, BA; Saad, F | 1 |
| Nelson, PS | 2 |
| Antonarakis, ES; Carducci, MA; Chen, Y; De Marzo, AM; Denmeade, SR; Eisenberger, MA; Fedor, HL; Isaacs, JT; Isaacs, WB; Lotan, TL; Lu, C; Luber, B; Luo, J; Mohammad, TA; Nadal, R; Nakazawa, M; Paller, CJ; Roeser, JC; Wang, H; Zheng, Q | 1 |
| Attard, G; de Bono, JS; Grist, E | 1 |
| DiPippo, VA; Han, AQ; Magargal, WW; Moorji, SM; Murga, JD; Olson, WC | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Roviello, G | 1 |
| Afshar, M; Al-Alloosh, F; James, ND; Pirrie, S; Porfiri, E; Rowan, C | 1 |
| De Maeseneer, DJ; Lumen, N; Rottey, S; Van Praet, C | 1 |
| Cho, E; Dalkin, BL; Konodi, MA; Kurland, BF; Liao, JJ; Marck, BT; Matsumoto, AM; Montgomery, RB; Mostaghel, EA; Russell, KJ | 1 |
| Bristow, RG; Dal Pra, A; Locke, JA; Supiot, S; Warde, P | 1 |
| Abajo Del Álamo, C; Catalá Pindado, MÁ; Godoy Díez, M; Moreno Gómez, Á | 1 |
| Kosaka, T; Oya, M | 1 |
| Fenner, A | 1 |
| Alyamani, M; Auchus, RJ; Bishop, AC; Bunch, D; Dreicer, R; Garcia, JA; Li, Z; Liu, J; Sharifi, N; Upadhyay, SK | 1 |
| Antonarakis, ES; Maughan, BL | 1 |
| Plymate, S; Sprenger, C; Uo, T | 1 |
| Benoist, GE; Gerritsen, WR; Kramers, C; Mulders, PF; Schers, HJ; van Erp, PH; Westdorp, H | 1 |
| Culig, Z; Dietrich, D; Eigentler, A; Handle, F; Hoefer, J; Hoogland, M; Klocker, H; Kristiansen, G; Neuwirt, H; Puhr, M; Sailer, V; Schlick, B; Uhl, B; van Leenders, G | 1 |
| Bowden, M; Christie, A; Huang, Y; Kantoff, PW; Lee, GS; Sweeney, CJ; Wang, X | 1 |
| Bíró, K; Géczi, L; Küronya, Z; Németh, H | 1 |
| Ohlmann, CH | 1 |
| Sidaway, P | 1 |
| Burchardt, M; Grossebrummel, H; Jensen, F; Knabbe, C; Mandelkow, R; Muzzio, D; Peter, T; Stope, MB; Walther, R; Weiss, M; Zimmermann, U; Zygmunt, M | 1 |
| Wadman, M | 1 |
| Beckmann, L; Bender, R; Lange, S | 1 |
| Palapattu, GS | 1 |
| Abbott, DH; Bird, IM | 1 |
| Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K | 1 |
| Abazeed, M; Alyamani, M; Auchus, RJ; Balk, SP; Li, J; Li, Z; Rogacki, K; Sharifi, N; Taplin, ME; Upadhyay, SK | 1 |
| Thoma, C | 1 |
| Abderrahman, B; Bhattacharya, P; Fan, P; Hawsawi, YM; Jordan, VC; Maximov, PY; Pokharel, N | 1 |
| Antonarakis, ES | 1 |
| Dick, B; Hartmann, RW; Hu, Q; Pandey, AV; Udhane, SS | 1 |
| Bonomo, S; Hansen, CH; Jørgensen, FS; Olsen, L; Petrunak, EM; Scott, EE; Styrishave, B | 1 |
| Bordeau, BM; Callahan, BP; Ciulla, DA | 1 |
| Akbor, M; Culig, Z; Handle, F; Heidegger, I; Hoefer, J; Klocker, H; Ofer, P; Parson, W; Puhr, M | 1 |
| Aghai, A; Böttcher, R; Burger, H; de Morrée, ES; de Ridder, CM; de Wit, R; Gibson, AA; Mathijssen, RH; Sparreboom, A; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Ando, T; Hara, N; Ishizaki, F; Miyashiro, Y; Nishiyama, T; Takeda, K; Takizawa, I; Tomita, Y | 1 |
| He, W; Huang, J; Lu, Z; Pan, C; Wei, D; Yan, F; Yi, X; Yuan, J; Zhang, J; Zhang, K; Zheng, W | 1 |
| Boysen, G; de Bono, J; Marzo, AM; Rodrigues, DN; Seed, G; Sumanasuriya, S | 1 |
| Armstrong, CM; Evans, CP; Gao, AC; Liu, C; Lombard, A; Lou, W | 1 |
| Antonarakis, ES; Attard, G | 1 |
| Ledet, EM; Lewis, BE; Sartor, O; Schiff, JP | 1 |
| Klein, EA; Raghavan, D | 1 |
| Attard, G; Barrett, M; Clark, J; Cooper, CS; de Bono, JS; Dearnaley, D; Dowsett, M; Folkerd, E; Kaye, SB; Lee, G; Martins, V; Parker, C; Raynaud, F; Reid, AH; Settatree, S; Yap, TA | 1 |
| Cole, A | 1 |
| Attard, G; De Bono, JS; Dearnaley, D; Reid, AH | 1 |
| Ang, JE; de Bono, JS; Olmos, D | 1 |
| A'Hern, R; Attard, G; Carden, CP; Cooper, CS; Coumans, F; Cox, ME; de Bono, JS; Dearnaley, D; Hawche, G; Jameson, C; Kaye, SB; Levink, R; Molina, A; Moreira, J; Olmos, D; Oommen, NB; Parker, C; Reid, AH; Riisnaes, R; Sipkema, R; Swennenhuis, JF; Terstappen, LW; Thompson, E; Vickers, E | 1 |
| Ryan, CJ; Van Allen, EM | 1 |
| A'Hern, R; Attard, G; de Bono, JS; Dearnaley, D; Dowsett, M; Folkerd, E; Kaye, SB; Kheoh, T; Lee, G; Maier, G; Messiou, C; Molife, LR; Molina, A; Olmos, D; Oommen, NB; Parker, C; Reid, AH; Sinha, R; Thompson, E | 1 |
| Attard, G; de Bono, JS; Olmos, D; Reid, AH | 1 |
| Patten, DY; Sartor, O | 1 |
| Josephson, DY; Pal, SK; Twardowski, P | 1 |
| Attard, G; Cooper, CS; de Bono, JS | 1 |
| Raghavan, D; Shepard, DR | 1 |
| Albiges, L; Blesius, A; de La Motte Rouge, T; Escudier, B; Fizazi, K; Gross-Goupil, M; Loriot, Y; Massard, C | 1 |
| Anand, A; Bubley, GJ; Danila, DC; de Bono, JS; Denmeade, SR; Fleisher, M; Haqq, C; Kheoh, T; Koscuiszka, M; Larson, SM; Molina, A; Morris, MJ; Ryan, CJ; Scher, HI; Schwartz, LH; Smith, MR; Taplin, ME | 1 |
| Attard, G; Danila, DC; de Bono, JS; Dearnaley, D; Fong, PC; Hunt, J; Kheoh, T; Lee, G; Messiou, C; Molife, LR; Molina, A; Olmos, D; Oommen, NB; Parker, C; Reid, AH; Ryan, CJ; Scher, HI; Small, E; Swennenhuis, JF; Terstappen, LW | 1 |
| Fong, L; Kantoff, P; Kheoh, T; Kim, J; Lee, G; Martins, V; Molina, A; Raynaud, F; Rosenberg, JE; Ryan, CJ; Small, EJ; Smith, MR | 1 |
| Ryan, C; Shah, S | 1 |
| Agarwal, N; Hutson, TE; Sonpavde, G; Vogelzang, NJ | 1 |
| Hara, T; Kusaka, M; Yamaoka, M | 1 |
| Attard, G; de Bono, JS; Reid, AH | 1 |
| Pal, SK; Sartor, O | 3 |
| Chowdhury, S; Harper, P; Powles, T | 1 |
| De-Bono, J; Massard, C; Zivi, A | 1 |
| Mohler, JL; Pantuck, AJ | 1 |
| Schmidt, C | 1 |
| Garcia, JA; Salem, M | 1 |
| Flaig, TW; Rove, KO | 1 |
| Ryan, C | 1 |
| Aljumaily, R; Mathew, P | 1 |
| Goetz, D | 1 |
| Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R | 1 |
| Sonpavde, G; Sternberg, CN | 1 |
| Djavan, B; Farr, A; Herout, R; Margreiter, M; Tosev, G | 1 |
| Petrylak, DP | 1 |
| Attard, G; Bellmunt, J; Malavaud, B; Mason, MD; Sonpavde, G; Sternberg, CN; Tombal, B | 1 |
| Thompson, CA | 1 |
| Bianchini, D; Cheng, T; Chi, KN; Chieffo, N; Chu, L; de Bono, JS; Efstathiou, E; Ellard, SL; Fizazi, K; Flaig, TW; Fléchon, A; Goodman, OB; Hainsworth, JD; Haqq, CM; Harland, S; Hutson, TE; Jones, RJ; Kheoh, T; Logothetis, CJ; Loriot, Y; Mainwaring, P; Molina, A; North, S; Patterson, H; Ryan, CJ; Saad, F; Saleh, M; Scher, HI; Scholz, M; Staffurth, JN; Sternberg, CN; Zivi, A | 1 |
| Bates, SE | 1 |
| Balk, SP; Cai, C | 1 |
| Ates-Alagoz, Z; Brodie, AM; Bruno, RD; Gediya, LK; Godbole, AM; Njar, VC; Purushottamachar, P; Vasaitis, TS | 1 |
| Efstathiou, E; Kirkpatrick, P; Logothetis, CJ; Manuguid, F | 1 |
| Balk, S; Marck, BT; Matsumoto, AM; Montgomery, RB; Mostaghel, EA; Nelson, PS; Plymate, SR; Vessella, RL | 1 |
| Carmichael, C; Josephson, DY; Pal, SK; Sartor, O; Vasani, D | 1 |
| Gelpi, F; Gomella, LG; Kelly, WK | 1 |
| Beltran, H; Tagawa, ST | 1 |
| Sonpavde, G | 1 |
| Berruti, A; Pia, A; Terzolo, M | 1 |
| Balk, SP; Bubley, GJ; Cai, C; Chen, S; Marck, B; Matsumoto, AM; Mostaghel, EA; Nelson, PS; Ng, P; Simon, NI; Wang, H | 1 |
| Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ | 1 |
| Higano, CS | 1 |
| Redding, MB; Surati, M | 1 |
| de Bono, JS; Massard, C; Michels, RM; Sartor, O | 1 |
| Börgermann, C; Molitor, B | 1 |
| Arlt, W; Attard, G; Auchus, RJ; Cassidy, AM; de Bono, JS; Dowsett, M; Folkerd, E; Hughes, BA; Oommen, NB; Reid, AH; Thompson, E | 1 |
| Cinar, B; Collak, FK; Soifer, HS; Souleimanian, N; Stein, CA; Voskresenskiy, AM; Wu, S | 1 |
| Chieffo, N; Efstathiou, E; Hoang, A; Karlou, M; Logothetis, CJ; Molina, A; Smith, LA; Titus, M; Troncoso, P; Tsavachidou, D; Tzelepi, V; Wen, S | 1 |
| Goozner, M | 1 |
| DeVore, NM; Scott, EE | 1 |
| Courtney, KD; Taplin, ME | 1 |
| Gschwend, JE; Heck, MM; Höppner, M; Horn, T; Retz, M; Thalgott, M | 1 |
| Fong, MK; Hare, R; Jarkowski, A | 1 |
| Ryan, CJ | 1 |
| Arlt, W; Attard, G; Carreira, S; de Bono, JS; Goodall, J; Hay, CW; Lim, AC; McEwan, IJ; Nowakowska, K; Pezaro, C; Richards, J; Taylor, AE; Wingate, A | 1 |
| Bahl, A; De Bono, J; Mason, M; Payne, H; Troup, J | 1 |
| Di Bisceglie, M; Moraca, L; Romito, S; Sasso, N; Sepede, C; Suriano, A; Turitto, G | 1 |
| Dipaola, RS; Goodin, S; Stein, MN | 1 |
| Beatty, J; Bell, R; Miller, M; Mohammed, A; Rawlinson, A | 1 |
| Herchenhorn, D; Maluf, FC; Smaletz, O | 1 |
| Kim, W; Ryan, CJ | 1 |
| Kmietowicz, Z | 1 |
| Bluemn, E; Edwards, J; Gurel, M; Hu, R; Isaacs, WB; Lu, C; Luo, J; Mostaghel, EA; Nelson, PS; Plymate, SR; Tannahill, C; Yegnasubramanian, S | 1 |
| Attard, G; Baikady, B; Bianchini, D; de Bono, J; Hunt, J; Maier, G; Mezynski, J; Mulick Cassidy, A; Olmos, D; Pezaro, C; Reid, AHM; Sandhu, S; Sarvadikar, A; Sheridan, E; Thompson, E; Zivi, A | 1 |
| Gottfried, M; Keizman, D; Maimon, N | 1 |
| Ratain, MJ | 1 |
| Albiges, L; Escudier, B; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Aapro, MS | 1 |
| de Bono, J; Ferraldeschi, R; Karavasilis, V; Pezaro, C | 1 |
| Adler, AI; Dyer, M; George, E; Rinaldi, F | 1 |
| Chang, KH; Sharifi, N | 1 |
| Lewis, B; Pal, SK; Sartor, O | 1 |
| Shah, BK; Shrestha, S | 1 |
| Cersosimo, RJ | 1 |
| Kuczyk, MA; Merseburger, AS; Wolff, JM | 1 |
| Cheng, ML; Ryan, CJ | 1 |
| Petrányi, Á | 1 |
| Birtle, A | 1 |
| Culine, S; Ouzaid, I; Pouessel, D; Ravery, V | 1 |
| Leroux, F | 1 |
| Attard, G; Belldegrun, AS; de Bono, JS | 1 |
| Hosaka, M; Takeda, M | 1 |
103 review(s) available for abiraterone and Cancer of Prostate
| Article | Year |
|---|---|
Recognition and Treatment of Adrenal Insufficiency Secondary to Abiraterone: A Case Report and Literature Review.
Topics: Adrenal Insufficiency; Aged; Androstenes; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2019 |
Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance.
Topics: Androgen Antagonists; Androstenes; Benzamides; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2020 |
Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms; Retrospective Studies | 2020 |
The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis.
Topics: Androgen Antagonists; Androstenes; Benzamides; Disease-Free Survival; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms | 2020 |
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Grading; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer.
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2020 |
Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Hormones; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome | 2020 |
The evolving options in metastatic castration-sensitive prostate cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions.
Topics: Androstenes; Animals; Benzamides; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, LHRH; Signal Transduction | 2020 |
Contemporary management of advanced prostate cancer: an evolving landscape.
Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational | 2021 |
Cardiovascular Toxicities of Androgen Deprivation Therapy.
Topics: Androstenes; Antineoplastic Agents, Hormonal; Cardiotoxicity; Cardiovascular Diseases; COVID-19; Disease Susceptibility; Gonadotropin-Releasing Hormone; Health Status Disparities; Humans; Male; Prostatic Neoplasms; SARS-CoV-2 | 2021 |
The role of bone-targeted therapies for prostate cancer in 2017.
Topics: Androstenes; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
Topics: Androgen Antagonists; Androstenes; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Progression-Free Survival; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2018 |
Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Humans; Male; Neoplasms, Hormone-Dependent; Patient Selection; Prednisolone; Prednisone; Prostatic Neoplasms; Treatment Outcome | 2017 |
Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.
Topics: Androgen Receptor Antagonists; Androstenes; Antigens, Surface; Benzamides; Bridged-Ring Compounds; Drug Discovery; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Receptors, Androgen; Taxoids; Tissue Extracts | 2018 |
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Evidence-Based Medicine; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2018 |
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.
Topics: Androstenes; Benzamides; Cardiovascular Diseases; Disease-Free Survival; Humans; Hypertension; Incidence; Male; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2018 |
Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Humans; Male; Mutation; Neoplasm Metastasis; Prostatic Neoplasms | 2018 |
New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Gene Amplification; Humans; Male; Molecular Chaperones; Molecular Targeted Therapy; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen | 2018 |
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Diphosphonates; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Treatment Outcome | 2018 |
Treatment of hormone-naïve metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Asia, Eastern; Asia, Southeastern; Combined Modality Therapy; Consensus; Developing Countries; Docetaxel; Humans; Lymph Node Excision; Male; Neoplasm Metastasis; Oceania; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Risk Factors | 2019 |
Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2018 |
Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
Topics: Androgen Receptor Antagonists; Androstenes; Anilides; Benzamides; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2019 |
[DNA damage repair: An emerging strategy in metastatic prostate cancer].
Topics: Androstenes; Antineoplastic Agents; Benzamides; DNA Damage; DNA Repair; Docetaxel; Genomic Instability; Humans; Male; Nitriles; Phenylthiohydantoin; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Retrospective Studies; Taxoids; Thiohydantoins; Tissue Extracts | 2019 |
[Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)].
Topics: Androstenes; Antineoplastic Agents, Hormonal; Humans; Male; Prednisone; Prostatic Neoplasms | 2019 |
Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future.
Topics: Androstenes; Docetaxel; Humans; Male; Medical Oncology; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic | 2019 |
Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Topics: Androgen Antagonists; Androstenes; Combined Modality Therapy; Docetaxel; Humans; Lymph Node Excision; Male; Metastasectomy; Neoplasm Metastasis; Prostatic Neoplasms; Standard of Care | 2019 |
[Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome | 2019 |
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2019 |
New agents in the arsenal to fight castrate-resistant prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Benzamides; Cancer Vaccines; Combined Modality Therapy; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts; United States | 2013 |
[Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].
Topics: Abatacept; Aminoglycosides; Androstenes; Androstenols; Anti-Bacterial Agents; Antineoplastic Agents; Clostridioides difficile; Clostridium Infections; Enzyme Inhibitors; Fidaxomicin; Humans; Immunoconjugates; Immunosuppressive Agents; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Thyroid Neoplasms | 2013 |
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.
Topics: Adrenocorticotropic Hormone; Androstenes; Androstenols; Humans; Male; Mineralocorticoid Excess Syndrome, Apparent; Mineralocorticoids; Prostatic Neoplasms | 2013 |
[Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
Topics: Androstenedione; Androstenes; Androstenols; Animals; Antineoplastic Agents; Dehydroepiandrosterone; Dihydrotestosterone; Enzyme Inhibitors; Humans; Male; Molecular Structure; Pregnenolone; Progesterone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Testosterone | 2013 |
New treatment options for castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Cancer Vaccines; Clinical Trials as Topic; Fees, Pharmaceutical; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2013 |
Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Benzamides; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Testosterone | 2014 |
[Novel drugs provide better therapy for prostate cancer].
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids | 2013 |
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Benzamides; Castration; Clinical Trials as Topic; Denosumab; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2013 |
Recent advances revolutionize treatment of metastatic prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Benzamides; Disease-Free Survival; Hormone Replacement Therapy; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Tissue Extracts | 2013 |
[New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Survival Rate | 2013 |
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
Topics: Androstenes; Androstenols; Biomarkers, Tumor; Enzyme Inhibitors; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2014 |
Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Animals; Antineoplastic Agents; Benzamides; Dehydroepiandrosterone; Endocrinology; Gonadotropin-Releasing Hormone; Humans; Male; Mutation; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Testosterone; Treatment Outcome | 2015 |
Androgen receptor splice variants in the era of enzalutamide and abiraterone.
Topics: Alternative Splicing; Androstenes; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2014 |
Pathologic fracture in patients with metastatic prostate cancer.
Topics: Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Zoledronic Acid | 2014 |
Targeting extra-gonadal androgens in castration-resistant prostate cancer.
Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Steroids | 2015 |
Prostate cancer in 2014: The year chemotherapy finally gets some respect!
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.
Topics: Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2015 |
Synergistic action of image-guided radiotherapy and androgen deprivation therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Biomarkers; Combined Modality Therapy; Dose-Response Relationship, Radiation; Flutamide; Goserelin; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiotherapy, Image-Guided; Risk Assessment; Treatment Outcome | 2015 |
Androgen pathway resistance in prostate cancer and therapeutic implications.
Topics: Androgens; Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Point Mutation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Splicing; Receptors, Androgen; Signal Transduction | 2015 |
[Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone; Treatment Outcome | 2015 |
[Treatment strategies for advanced prostate cancer].
Topics: Adrenal Cortex Hormones; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Denosumab; Drug Administration Schedule; Drug Approval; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2015 |
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Topics: Adrenal Hyperplasia, Congenital; Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Male; Naphthalenes; Prednisone; Prostate; Prostatic Neoplasms; Protective Factors; Steroid 17-alpha-Hydroxylase; Triazoles | 2016 |
Prostate cancer: Interfering with abiraterone metabolism to optimize therapy.
Topics: Androstenes; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase | 2016 |
The molecular underpinnings of prostate cancer: impacts on management and pathology practice.
Topics: Androstenes; Animals; Biomarkers; Humans; Male; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction | 2017 |
Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2016 |
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Male; Models, Biological; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Failure | 2009 |
Novel secondary hormonal therapy in advanced prostate cancer: an update.
Topics: Androgen Antagonists; Androstenes; Androstenols; Disease Progression; Humans; Ketoconazole; Male; Prostatic Neoplasms; Receptors, Androgen | 2009 |
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
Topics: Androstenes; Androstenols; Biomarkers, Tumor; Enzyme Inhibitors; Humans; Male; Orchiectomy; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2009 |
New therapeutic agents for castration-refractory prostate cancer.
Topics: Androstenes; Androstenols; Benzamides; Endothelins; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Protein Kinase Inhibitors; Receptors, Androgen; Thalidomide; Tissue Extracts | 2009 |
Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Benzamides; Castration; Clinical Trials as Topic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2009 |
Innovations in the systemic therapy of prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Delivery Systems; Drugs, Investigational; Humans; Male; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Survival Analysis | 2010 |
Abiraterone acetate for castration resistant prostate cancer.
Topics: Androstenes; Androstenols; Animals; Clinical Trials, Phase II as Topic; Humans; Male; Orchiectomy; Prostatic Neoplasms; Signal Transduction | 2010 |
Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms | 2010 |
Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer.
Topics: Androgens; Androstenes; Androstenols; Disease Progression; Humans; Male; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase | 2010 |
Changing therapeutic paradigms in castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Benzamides; Clinical Trials, Phase III as Topic; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Testosterone | 2010 |
Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Topics: Adrenal Glands; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Humans; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Steroid 17-alpha-Hydroxylase | 2011 |
A renaissance in the medical treatment of advanced prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; RANK Ligand; Taxoids; Tissue Extracts | 2010 |
Abiraterone in prostate cancer.
Topics: Androstenes; Androstenols; Humans; Male; Prostatic Neoplasms | 2010 |
New options for the management of castration-resistant prostate cancer: a case perspective.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Immunotherapy; Male; Prostatectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure | 2011 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts | 2011 |
Contemporary management of metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Castration; Denosumab; Drug Therapy; Humans; Male; Prostatic Neoplasms; RANK Ligand; Taxoids; Testicular Neoplasms; Tissue Extracts | 2011 |
Current clinical trials in castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Neovascularization, Pathologic; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Enzyme Inhibitors; Evidence-Based Medicine; Humans; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2011 |
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.
Topics: Androgens; Androstenes; Androstenols; Enzyme Inhibitors; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen | 2011 |
Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Animals; Humans; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Steroid 17-alpha-Hydroxylase | 2011 |
New treatment options for castrate-resistant prostate cancer: a urology perspective.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2011 |
Novel therapies for metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Radioisotopes; Taxoids; Tissue Extracts | 2011 |
[Second line therapy for castration-resistant prostate cancer (CRPC)].
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Survival Rate; Taxoids; Tissue Extracts | 2012 |
The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Benzimidazoles; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Thiohydantoins | 2012 |
A new era for castrate resistant prostate cancer: a treatment review and update.
Topics: Androstenes; Androstenols; Animals; Antineoplastic Agents; Drug Approval; Humans; Male; Molecular Targeted Therapy; Orchiectomy; Prostatic Neoplasms; Survival Rate; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration | 2012 |
[Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Drug Resistance, Neoplasm; Humans; Male; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2012 |
Abiraterone in prostate cancer: a new angle to an old problem.
Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Clinical Trials as Topic; Humans; Male; Orchiectomy; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2012 |
The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 2012 |
Castration-resistant prostate cancer: systemic therapy in 2012.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Evidence-Based Medicine; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Thiohydantoins | 2012 |
Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
Topics: Androgen Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antineoplastic Agents; Cancer Vaccines; Cathepsin K; Dendritic Cells; Docetaxel; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Radiopharmaceuticals; RANK Ligand; Receptors, Endothelin; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; src-Family Kinases; Taxoids; Tissue Extracts | 2014 |
Management of advanced prostate cancer in senior adults: the new landscape.
Topics: Aged; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Castration; Clinical Trials as Topic; Disease Management; Docetaxel; Drug Resistance, Neoplasm; Humans; Life Expectancy; Male; Prostate; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Castration; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2013 |
Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Failure | 2012 |
New agents for the management of castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Castration; Humans; Male; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
[Pathophysiology and therapy of castration-resistant prostate cancer].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers, Tumor; Disease Progression; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Naphthalenes; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms | 2013 |
Abiraterone acetate for the treatment of prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Androstenes; Androstenols; Antineoplastic Agents; Castration; Disease Progression; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen | 2013 |
[The treatment of castration-resistant prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cancer Vaccines; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Oligonucleotides, Antisense; Orchiectomy; Prostatic Neoplasms; Protein-Tyrosine Kinases; RANK Ligand; Receptors, Vascular Endothelial Growth Factor; Taxoids; Tissue Extracts; Treatment Failure | 2012 |
Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids | 2013 |
[Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Denosumab; Disease-Free Survival; France; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Tissue Extracts; Treatment Outcome | 2013 |
Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Enzyme Inhibitors; Humans; Imidazoles; Inhibitory Concentration 50; Male; Molecular Structure; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2005 |
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Androstenols; Animals; Drug Evaluation; Humans; Lyases; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2005 |
[Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Topics: 17-Hydroxysteroid Dehydrogenases; Androgen Antagonists; Androstenes; Androstenols; Animals; Antineoplastic Agents, Hormonal; Carbazoles; Enzyme Inhibitors; Humans; Imidazoles; Ketoconazole; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Testosterone | 2000 |
22 trial(s) available for abiraterone and Cancer of Prostate
| Article | Year |
|---|---|
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Quality of Life | 2022 |
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Female; Humans; Hypertension; Male; Prednisone; Prostatic Neoplasms | 2022 |
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
Topics: Abiraterone Acetate; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 2023 |
Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
Topics: Aged; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Double-Blind Method; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms; Risk Assessment; Treatment Outcome | 2021 |
'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial.
Topics: Androstenes; Antineoplastic Agents; Data Interpretation, Statistical; Docetaxel; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2017 |
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.
Topics: Androgens; Androstenes; Disease Progression; Humans; Male; Models, Theoretical; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Testosterone; Time Factors; Treatment Failure; Treatment Outcome | 2017 |
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Topics: Aged; Androstenes; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzamides; Biomarkers, Tumor; BRCA2 Protein; Circulating Tumor DNA; Drug Resistance, Neoplasm; Exome Sequencing; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Treatment Outcome | 2018 |
Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Radiotherapy; Taxoids; Treatment Outcome; Tubulin Modulators | 2019 |
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Humans; Kallikreins; Leuprolide; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm, Residual; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome; United States | 2019 |
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Topics: Aged; Androstenes; Androstenols; Antineoplastic Agents; Bone Neoplasms; BRCA2 Protein; Humans; Male; Middle Aged; Mutation; Neoplasm Grading; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms | 2013 |
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Body Composition; Humans; Male; Maximum Tolerated Dose; Middle Aged; Orchiectomy; Prostatic Neoplasms; Retrospective Studies; Sarcopenia; Treatment Failure | 2013 |
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytochrome P-450 Enzyme Inhibitors; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms; Research Design; Steroid 17-alpha-Hydroxylase; Switzerland; Treatment Outcome; United Kingdom | 2014 |
External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.
Topics: Androgen Antagonists; Androgens; Androstenes; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Neoadjuvant Therapy; Prednisone; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Time Factors | 2015 |
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androstenes; Androstenols; Castration; Disease Progression; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Treatment Outcome | 2008 |
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Testosterone | 2009 |
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Glucocorticoids; Humans; Hyperaldosteronism; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids | 2010 |
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Ketoconazole; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2010 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Fatigue; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Survival Analysis; Treatment Outcome | 2011 |
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Pharmacological; Carcinoma; Chemotherapy, Adjuvant; Disease Progression; Enzyme Inhibitors; Glucocorticoids; Humans; Male; Models, Biological; Orchiectomy; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2012 |
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Bone Marrow; Bone Neoplasms; Castration; Disease-Free Survival; Drug Administration Schedule; Fatigue; Histone Deacetylase Inhibitors; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Nausea; Prostatic Neoplasms; Receptors, Androgen; Remission Induction; Testosterone; Vascular Diseases; Young Adult | 2012 |
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone | 2012 |
217 other study(ies) available for abiraterone and Cancer of Prostate
| Article | Year |
|---|---|
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.
Topics: Cytochrome P-450 Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Steroids; Structure-Activity Relationship; Testis | 1995 |
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
Topics: Algorithms; Antineoplastic Agents; Azoles; Binding Sites; Enzyme Inhibitors; Humans; Hydrogen Bonding; Male; Models, Molecular; Prostatic Neoplasms; Protein Binding; Quantitative Structure-Activity Relationship; Steroid 17-alpha-Hydroxylase; Steroids | 2003 |
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Azoles; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Isoenzymes; Male; Mice; Mice, SCID; Mutation; Prostatic Neoplasms; Pyrazines; Radioligand Assay; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Tissue Distribution; Transcription, Genetic; Transcriptional Activation; Xenograft Model Antitumor Assays | 2005 |
Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Topics: Androstenes; Androstenols; Biphenyl Compounds; Enzyme Inhibitors; Humans; Male; Models, Molecular; Prostatic Neoplasms; Recombinant Proteins; Steroid 17-alpha-Hydroxylase | 2008 |
Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Topics: Antineoplastic Agents, Hormonal; Biphenyl Compounds; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Pyridines; Spectrometry, Mass, Electrospray Ionization; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Substrate Specificity | 2010 |
Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Topics: Androgen Antagonists; Animals; Biphenyl Compounds; Cell Line; Cricetinae; Cricetulus; Humans; Imidazoles; In Vitro Techniques; Male; Microsomes; Prostatic Neoplasms; Pyridines; Steroid 11-beta-Hydroxylase; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Testis | 2010 |
Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Cell Line; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Humans; Male; Models, Molecular; Naphthalenes; Prostatic Neoplasms; Pyridines; Steroid 11-beta-Hydroxylase; Steroid 17-alpha-Hydroxylase | 2013 |
17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
Topics: Androstanes; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Humans; Male; Molecular Docking Simulation; Prostate; Prostatic Neoplasms; Protein Binding; Steroid 17-alpha-Hydroxylase | 2013 |
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Topics: Androgen Receptor Antagonists; Androstadienes; Benzimidazoles; Clinical Trials as Topic; Drug Discovery; Humans; Male; Molecular Structure; Molecular Targeted Therapy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tissue Distribution | 2015 |
Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.
Topics: Androstenes; Animals; Cell Line; Drug Discovery; Humans; Inhibitory Concentration 50; Male; Prostatic Neoplasms; Pyridines; Rats; Rats, Sprague-Dawley; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Testosterone | 2017 |
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
Topics: Antineoplastic Agents; Histone Deacetylase Inhibitors; Histone Demethylases; Humans; Male; Pargyline; Prostatic Neoplasms | 2021 |
Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Androstenes; Anilides; Antineoplastic Combined Chemotherapy Protocols; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds | 2022 |
Time on treatment with abiraterone in men with
Topics: Androstenes; Castration; Drug Utilization; Humans; Male; Prostatic Neoplasms | 2022 |
Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.
Topics: Androstenes; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Quality of Life | 2022 |
Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Propensity Score; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2022 |
Cardiovascular and Metabolic Diagnoses Associated With Novel Hormonal Agents for Prostate Cancer in Nontrial Populations.
Topics: Androgen Antagonists; Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms | 2022 |
Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer.
Topics: Aged; Androstenes; Benzamides; Humans; Male; Medicare; Nitriles; Phenylthiohydantoin; Physicians; Prostatic Neoplasms; United States; Urology | 2022 |
[The interactions of abiraterone and its pharmacologically active metabolite D4A with cytochrome P450 2C9 (CYP2C9)].
Topics: Androstenes; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Heme; Humans; Iron; Male; Prostatic Neoplasms | 2022 |
Targeted non AR mediated smart delivery of abiraterone to the prostate cancer.
Topics: Androstenes; Apoptosis; Cell Line, Tumor; Gold; Humans; Male; Metal Nanoparticles; Prostatic Neoplasms; Survivin | 2022 |
Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms | 2022 |
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
Topics: Antineoplastic Agents; Binding Sites; Cytochrome P-450 Enzyme System; Humans; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Steroids | 2023 |
Instrumental and transcriptome analysis reveals the chemotherapeutic effects of doxorubicin-loaded black phosphate nanosheets on abiraterone-resistant prostate cancer.
Topics: Androgen Antagonists; Doxorubicin; Gene Expression Profiling; Humans; Male; Phosphates; Prostatic Neoplasms; Treatment Outcome | 2023 |
Validation of an LC-MS/MS method for simultaneous quantification of abiraterone, enzalutamide and darolutamide in human plasma.
Topics: Chromatography, Liquid; Humans; Male; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Tandem Mass Spectrometry | 2023 |
Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study.
Topics: Androgen Antagonists; Androstenes; Case-Control Studies; Humans; Male; Neoplasm Metastasis; Progression-Free Survival; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol.
Topics: Aldo-Keto Reductase Family 1 Member C3; Androstenes; Dehydroepiandrosterone Sulfate; Humans; Male; Prostatic Neoplasms; Testosterone; Testosterone Congeners | 2023 |
Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
Topics: Androstenes; Cost-Benefit Analysis; Docetaxel; Humans; Male; Prostatic Neoplasms | 2019 |
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Drug Combinations; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment | 2019 |
Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.
Topics: Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Humans; Japan; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2020 |
Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Cardiotoxicity; Databases, Factual; Heart Failure; Humans; Male; Middle Aged; Nitriles; Pharmacovigilance; Phenylthiohydantoin; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Tachycardia, Supraventricular; Time Factors | 2020 |
New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Network Meta-Analysis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Thiohydantoins | 2020 |
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer.
Topics: Administration, Oral; Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins | 2020 |
Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
Topics: Androgen Antagonists; Androstenes; Animals; Antineoplastic Agents; Castration; Cell Line, Tumor; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Male; Mice; Prostatic Neoplasms; Protein Isoforms; Receptors, Androgen; Taxoids; Transcriptome; Xenograft Model Antitumor Assays | 2020 |
Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer - Playing the Right CARD.
Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids | 2019 |
Re: Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids | 2020 |
Nodal Recurrence From Prostate Adenocarcinoma: Curable or Incurable?
Topics: Adenocarcinoma; Androstenes; Carboxylic Acids; Combined Modality Therapy; Cyclobutanes; Gonadotropin-Releasing Hormone; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Irradiation; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms | 2020 |
Re:Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids | 2020 |
Abiraterone acetate treatment lowers 11-oxygenated androgens.
Topics: Abiraterone Acetate; Adrenal Hyperplasia, Congenital; Adult; Androgens; Androstenes; Chromatography, Liquid; Cytochrome P-450 Enzyme Inhibitors; Drug Therapy, Combination; Humans; Male; Prednisone; Prostatic Neoplasms; Tandem Mass Spectrometry; Testosterone | 2020 |
Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer.
Topics: Androstenes; Benzamides; Humans; Male; Medical Oncology; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms | 2020 |
Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets.
Topics: Abiraterone Acetate; Androstenes; Humans; India; Male; Prostatic Neoplasms | 2020 |
Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids | 2020 |
Cabazitaxel in Metastatic Prostate Cancer.
Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids | 2020 |
The ligand exchange of citrates to thioabiraterone on gold nanoparticles for prostate cancer therapy.
Topics: Androstenes; Cell Line; Cell Survival; Citrates; Epithelial Cells; Gold; Humans; Ligands; Liver; Male; Metal Nanoparticles; Prostate; Prostatic Neoplasms; Sulfhydryl Compounds | 2020 |
Low-Dose Abiraterone, a Rare European Commodity.
Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prostatic Neoplasms | 2020 |
Potential Cost Savings With Low-Dose Abiraterone in the United States.
Topics: Androstenes; Cost Savings; Humans; Male; Prostatic Neoplasms; United States | 2020 |
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Confidence Intervals; Cost-Benefit Analysis; Docetaxel; Humans; Male; Markov Chains; Monte Carlo Method; Prednisone; Prostatic Neoplasms; Quality-Adjusted Life Years; Radiosurgery; Salvage Therapy; Time Factors | 2020 |
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
Topics: Androstenes; Cell Line, Tumor; Dehydroepiandrosterone; Enzyme Inhibitors; Humans; Kinetics; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Steroids | 2020 |
Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
Topics: Androstenes; Celecoxib; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2020 |
PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; Benzamides; Combined Modality Therapy; Gonadotropin-Releasing Hormone; Health Care Surveys; Humans; Italy; Male; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiation Oncologists; Risk Factors; Salvage Therapy | 2021 |
Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Drug Costs; Health Expenditures; Humans; Income; Insurance Coverage; Male; Medicare Part D; Medication Adherence; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Retrospective Studies; United States | 2020 |
Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Benzamides; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; RNA-Seq; Steryl-Sulfatase | 2020 |
Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients.
Topics: Androstenes; Chromatography, Liquid; Dried Blood Spot Testing; Drug Monitoring; Humans; Male; Prostatic Neoplasms; Reproducibility of Results; Tandem Mass Spectrometry | 2021 |
Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells.
Topics: Androgen Antagonists; Androstenes; Cell Line, Tumor; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Male; Neoplasm Metastasis; Prostatic Neoplasms; Receptor, Notch1; RNA, Messenger; Transcription Factor HES-1 | 2021 |
Treatment-emergent neuroendocrine prostate cancer with a germline
Topics: Aged; Androstenes; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Drug Resistance, Neoplasm; Drug Therapy; Genes, BRCA1; Genes, BRCA2; Germ Cells; Humans; Male; Mutation; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms | 2021 |
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Docetaxel; Genes, BRCA1; Genes, BRCA2; Genetic Testing; Humans; Male; Medical Oncology; Nitriles; Orchiectomy; Phenylthiohydantoin; Phthalazines; Piperazines; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic; Societies, Medical; Spain; Thiohydantoins | 2021 |
Antihormone treatment differentially regulates PSA secretion, PSMA expression and
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antigens, Surface; Cell Line, Tumor; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Humans; Male; Oligopeptides; PC-3 Cells; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Secretory Pathway | 2021 |
Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.
Topics: Active Transport, Cell Nucleus; Androgen Antagonists; Androstenes; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Cell Nucleus; Cohort Studies; ErbB Receptors; Estrogen Receptor beta; Finasteride; Humans; Male; Mice; Mice, Knockout; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Phytoestrogens; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Receptors, Estrogen | 2021 |
Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Databases, Factual; Gonadotropin-Releasing Hormone; Heart Failure; Humans; Hypertension; Male; Middle Aged; Pharmacovigilance; Prostatic Neoplasms; Retrospective Studies; United States; United States Food and Drug Administration; Young Adult | 2021 |
Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds.
Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.
Topics: 3' Untranslated Regions; Androgen Antagonists; Androstenes; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; MicroRNAs; PC-3 Cells; Prostatic Neoplasms; Solute Carrier Organic Anion Transporter Family Member 1B3; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
Topics: Androstenes; Black or African American; Docetaxel; Georgia; Health Status Disparities; Hormones; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies | 2021 |
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
Topics: Aged; Aged, 80 and over; Alternative Splicing; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Clinical Decision-Making; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Liquid Biopsy; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms; Receptors, Androgen; Time Factors; Transcriptome; United States | 2021 |
Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Topics: Androgens; Androstenes; Antineoplastic Agents, Hormonal; Catalytic Domain; Cytochrome P-450 CYP3A; Enzyme Inhibitors; Humans; Imidazoles; Ketoconazole; Kinetics; Male; Naphthalenes; Pregnenolone; Progesterone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2021 |
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Progression-Free Survival; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
Primary signet ring cell carcinoma of the prostate with response to abiraterone.
Topics: Aged; Androstenes; Carcinoma, Signet Ring Cell; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2017 |
First-line abiraterone improves survival in prostate cancer.
Topics: Androgen Antagonists; Androstenes; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Steroid 17-alpha-Hydroxylase; Steroid Synthesis Inhibitors; Treatment Outcome | 2017 |
An Unusual Metastasis of Prostate Cancer to Duodenum.
Topics: Adenocarcinoma; Aged; Androstenes; Biopsy; Duodenal Neoplasms; Duodenum; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2016 |
Prostate cancer: STAMPEDE, LATITUDE and Fernand Labrie's legacy.
Topics: Androgen Antagonists; Androstenes; Humans; Male; Prostatic Neoplasms | 2017 |
[Androgen deprivation plus abiraterone/prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Humans; Male; Medical Oncology; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms; Treatment Outcome; Urology | 2017 |
Commentary on: "Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy." Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N. Nature. 2016 May 25;533(7604):547-51.
Topics: Androstenes; Humans; Male; Nonsteroidal Anti-Androgens; Prostatic Neoplasms | 2017 |
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity.
Topics: Amiloride; Androgens; Androstenes; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Humans; Hydrochlorothiazide; Male; Mineralocorticoid Excess Syndrome, Apparent; Mineralocorticoids; Prostatic Neoplasms | 2017 |
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Health Care Costs; Humans; Male; Markov Chains; Netherlands; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Quality-Adjusted Life Years; Radium; Treatment Failure | 2018 |
CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
Topics: Androgens; Androstenes; Cell Line, Tumor; Gonadal Steroid Hormones; Humans; Male; Pregnanolone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2017 |
CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Topics: Androstenes; Antineoplastic Agents; Cell Line, Tumor; Escherichia coli; Humans; Male; Molecular Docking Simulation; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Steroid 21-Hydroxylase; Steroids | 2017 |
[Prostate cancer and DNA repair genes].
Topics: Adult; Aged; Androstenes; Benzimidazoles; Clinical Trials as Topic; DNA Repair; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Middle Aged; Phthalazines; Piperazines; Prostatic Neoplasms | 2017 |
Abiraterone in Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Androstenols; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2017 |
Abiraterone in Metastatic Prostate Cancer.
Topics: Androstenes; Androstenols; Humans; Male; Prostatic Neoplasms | 2017 |
Abiraterone in Metastatic Prostate Cancer.
Topics: Androstenes; Androstenols; Humans; Male; Prostatic Neoplasms | 2017 |
Abiraterone in Metastatic Prostate Cancer.
Topics: Androstenes; Androstenols; Humans; Male; Prostatic Neoplasms | 2017 |
Abiraterone in Metastatic Prostate Cancer.
Topics: Androstenes; Androstenols; Humans; Male; Prostatic Neoplasms | 2017 |
Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; MCF-7 Cells; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Glucocorticoid | 2018 |
Expanding the use of abiraterone in prostate cancer: Is earlier always better?
Topics: Androstenes; Castration; Humans; Male; Prednisone; Prostatic Neoplasms | 2018 |
Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Testosterone | 2018 |
[Register for new drugs in cancer care provides a picture of how the drugs are used in the daily clinical practice].
Topics: Androstenes; Antineoplastic Agents; Benzamides; Bevacizumab; Breast Neoplasms; Colorectal Neoplasms; Drug Utilization; Humans; Ipilimumab; Male; Melanoma; Neoplasms; Nitriles; Palliative Care; Phenylthiohydantoin; Pilot Projects; Prostatic Neoplasms; Radium; Registries; Survival Rate; Sweden; Withholding Treatment | 2017 |
[Improved survival in advanced or metastatic prostate cancer with initial androgen deprivation and concomitant abiraterone].
Topics: Androgen Antagonists; Androstenes; Humans; Male; Prostatic Neoplasms | 2018 |
Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Androstenes; Castration; Humans; Male; Prednisone; Prostatic Neoplasms | 2018 |
Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Drug Prescriptions; Educational Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Residence Characteristics; Sweden; Time Factors | 2018 |
Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2018 |
Prostate cancer involving bilateral seminal vesicles along with bone and testicular metastases: a case report.
Topics: Adenocarcinoma; Aged; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Bone Neoplasms; Humans; Male; Neoplasm Grading; Orchiectomy; Physical Examination; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Seminal Vesicles; Testicular Neoplasms; Tomography, X-Ray Computed | 2018 |
Response to letter commenting on published paper: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Topics: Androstenes; Humans; Male; Prostatic Neoplasms | 2018 |
RE: Rydzewska et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 Oct; 84:88-101.
Topics: Androstenes; Humans; Male; Prostatic Neoplasms | 2018 |
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Glucocorticoids; Humans; Male; Prostatic Neoplasms; Survival Analysis; United States | 2018 |
The case for 'successfully' treating hormone naïve metastatic prostate cancer.
Topics: Androstenes; Docetaxel; Humans; Male; Prostatic Neoplasms | 2018 |
Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.
Topics: Androstenes; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Heterografts; Humans; Male; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mice, Transgenic; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2018 |
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Genotype; Humans; Male; Middle Aged; Multienzyme Complexes; Mutation, Missense; Neoplasm Proteins; Progesterone Reductase; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Steroid Isomerases | 2018 |
Therapeutic Discovery for Castration Resistant Prostate Cancer: Patient-derived Xenograft Modelling Brings New Options to the Table.
Topics: Androstenes; Benzamides; Heterografts; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Ribosomes | 2018 |
Improving outcome in patients with prostate and kidney cancer: heading in the right direction?
Topics: Androstenes; Antineoplastic Agents; Clinical Decision-Making; Humans; Immunotherapy; Kidney Neoplasms; Male; Neoplasm Metastasis; Patient Participation; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein-Tyrosine Kinases | 2018 |
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
Topics: Adenocarcinoma; Androstenes; Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antibody Affinity; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Female; Humans; Macaca fascicularis; Male; Membrane Cofactor Protein; Neuroendocrine Tumors; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Recombinant Fusion Proteins; Signal Transduction; Therapeutics; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer.
Topics: Androstenes; Disease Management; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Game Theory; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2018 |
Appendix 1: Cancer of the Prostate: eUpdate published online 28 September 2017 (http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate).
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Europe; Humans; Male; Medical Oncology; Practice Guidelines as Topic; Prednisolone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Societies, Medical; Treatment Outcome | 2018 |
Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron.
Topics: Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Binding Sites; Catalytic Domain; Cytochrome P-450 CYP1A1; Heme; Humans; Hydrophobic and Hydrophilic Interactions; Iron; Male; Molecular Docking Simulation; Prostatic Neoplasms; Protein Conformation, alpha-Helical | 2019 |
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.
Topics: Androstenes; Angiogenesis Inhibitors; Animals; Benzamides; Cell Line, Tumor; HSP70 Heat-Shock Proteins; Humans; Male; Mice; Molecular Docking Simulation; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Proteostasis; Receptors, Androgen; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination | 2018 |
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Biopsy, Large-Core Needle; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Orchiectomy; Prognosis; Progression-Free Survival; Prostate; Prostatic Neoplasms; Retrospective Studies; Risk Assessment | 2019 |
Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tubulin Modulators | 2019 |
An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives.
Topics: Androstenes; Antineoplastic Agents; Chromatography, Liquid; Drug Monitoring; Drug Stability; Glucuronides; Humans; Limit of Detection; Linear Models; Male; Prostatic Neoplasms; Reproducibility of Results; Tandem Mass Spectrometry | 2019 |
Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
Topics: Androgen Antagonists; Androstenes; Cohort Studies; Humans; Male; Multienzyme Complexes; Mutation, Missense; Progesterone Reductase; Prostatic Neoplasms; Steroid Isomerases; Treatment Outcome | 2019 |
Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently.
Topics: Androstenes; Cost of Illness; Docetaxel; Humans; Male; Molecular Biology; Neoplasm Metastasis; Phenotype; Positron-Emission Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Tubulin Modulators; Whole Body Imaging | 2019 |
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cost-Benefit Analysis; Docetaxel; Humans; Male; Placebos; Progression-Free Survival; Prostatic Neoplasms; Quality-Adjusted Life Years; Reference Values; Reproducibility of Results; Time Factors; Treatment Outcome | 2019 |
STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?
Topics: Androgen Antagonists; Androstenes; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Standard of Care | 2019 |
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; Humans; Immunomodulation; Lymphocyte Count; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; T-Lymphocytes | 2019 |
Re: Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
Topics: Androgen Antagonists; Androstenes; Benzamides; Humans; Leuprolide; Male; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms | 2019 |
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents.
Topics: Aged; Androstenes; Antibodies, Antinuclear; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Prednisone; Prostatic Neoplasms | 2019 |
Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Cell Line, Tumor; Cigarette Smoking; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen | 2019 |
Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Standard of Care; Tumor Burden | 2019 |
Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated Ranking.
Topics: Androstenes; Antineoplastic Agents, Immunological; Benzamides; Cadherins; Disease Progression; Epithelial Cell Adhesion Molecule; Humans; Magnetite Nanoparticles; Male; Neoplastic Cells, Circulating; Nitriles; Phenotype; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen | 2019 |
Dirty deeds done dirt cheap: sensitization of prostate cancer cells to abiraterone treatment using hydroxylated polychlorinated biphenyls.
Topics: Androstenes; Antineoplastic Agents; Cell Survival; Heat-Shock Proteins; Humans; Male; Molecular Chaperones; PC-3 Cells; Polychlorinated Biphenyls; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2020 |
Re: Evaluation of Intense Androgen Deprivation before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide with or without Abiraterone.
Topics: Androgen Antagonists; Androstenes; Benzamides; Humans; Leuprolide; Male; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms | 2019 |
Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How.
Topics: Androstenes; Benzamides; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Wnt Signaling Pathway | 2020 |
[New treatments for castration-resistant prostate cancer].
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Multicenter Studies as Topic; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2013 |
Abiraterone and castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Humans; Male; Orchiectomy; Prostatic Neoplasms | 2013 |
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2013 |
Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids | 2013 |
N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Apoptosis; Aromatase; Cell Line, Tumor; Cell Proliferation; DNA Cleavage; Humans; Male; MCF-7 Cells; Piperazines; Prostatic Neoplasms; Pyridines; Steroid 17-alpha-Hydroxylase; Steroids | 2013 |
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Disease Progression; Docetaxel; Estrogens, Non-Steroidal; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome | 2013 |
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.
Topics: Amino Acid Sequence; Androstenes; Androstenols; Animals; Base Sequence; Benzamides; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Gene Regulatory Networks; Humans; In Situ Hybridization, Fluorescence; Male; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Molecular Sequence Data; Nitriles; Oligonucleotide Array Sequence Analysis; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Protein Engineering; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid | 2014 |
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
Topics: Alternative Splicing; Androgen Antagonists; Androstenes; Androstenols; Animals; Castration; Drug Resistance, Neoplasm; Humans; Immunoblotting; Male; Mice; Prostatic Neoplasms; Protein Isoforms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays | 2014 |
Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.
Topics: Androgen Antagonists; Androstenes; Androstenols; Chemical and Drug Induced Liver Injury; Heart Diseases; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2014 |
[Usage, effectiveness and safety of abiraterone in prostate cancer].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies | 2014 |
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Androstenols; Biomarkers, Tumor; Bone Neoplasms; Chromogranin A; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2014 |
Experts condemn "flawed" NICE process over its rejection of prostate cancer drug.
Topics: Androstenes; Androstenols; Cost-Benefit Analysis; Drug Approval; Government Agencies; Humans; Male; National Health Programs; Prostatic Neoplasms; United Kingdom | 2014 |
Targeting the androgen receptor in prostate cancer--a resilient foe.
Topics: Androstenes; Androstenols; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; RNA, Neoplasm | 2014 |
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Topics: Androstenes; Androstenols; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Morphinans; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Survival Analysis | 2014 |
Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
Topics: Androgen Antagonists; Androstenes; Antibodies; Antigens, Surface; Benzamides; Cell Line, Tumor; Drug Delivery Systems; Glutamate Carboxypeptidase II; Humans; Immunoconjugates; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen | 2015 |
AR-V7 predicts prostate cancer treatment response.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Protein Isoforms; Receptors, Androgen; RNA, Messenger; Treatment Outcome | 2014 |
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Androstenes; Androstenols; Antineoplastic Agents; Humans; Kidney Function Tests; Male; Middle Aged; Prostatic Neoplasms; Renal Insufficiency, Chronic | 2014 |
Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer.
Topics: Adult; Aged; Androstenes; Antineoplastic Agents; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 2015 |
[Some questions about abiraterone, breakfast and public funding].
Topics: Androgen Receptor Antagonists; Androstenes; Breakfast; Drug Costs; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2015 |
[Effect and adverse event of enzalutamide and abiraterone in prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen | 2015 |
Prostate cancer: PSA kinetics predict survival in patients treated with abiraterone.
Topics: Androstenes; Biomarkers, Tumor; Disease Progression; Global Health; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 2015 |
Abiraterone: thrombocytopenia.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Drug Monitoring; Humans; Male; Patient Selection; Platelet Count; Predictive Value of Tests; Prostatic Neoplasms; Risk Assessment; Risk Factors; Thrombocytopenia; Time Factors; Treatment Outcome | 2014 |
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Receptor Antagonists; Androgens; Androstenes; Animals; Benzamides; Biosynthetic Pathways; Biotransformation; Cell Division; Chromatin; Dihydrotestosterone; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Survival Analysis; Xenograft Model Antitumor Assays | 2015 |
Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?
Topics: Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Humans; Male; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Protein Isoforms; Receptors, Androgen; Treatment Outcome | 2015 |
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.
Topics: Androgens; Androstenes; Benzamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Protein Inhibitors of Activated STAT; Protein Stability; Proteolysis; Receptors, Androgen; RNA, Messenger; Signal Transduction; Survival Analysis; Transcription, Genetic | 2016 |
Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
Topics: Androstenes; Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Antagonism; Drug Resistance, Neoplasm; Humans; Male; Mice; Phosphorylation; Prostatic Neoplasms; Pyridines; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Receptors, Androgen; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
[Chemotherapy of prostate cancer].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Therapy; Evidence-Based Medicine; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2015 |
Prostate cancer: Effectiveness of abiraterone is unaffected by prior ADT.
Topics: Androgen Antagonists; Androstenes; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2016 |
Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways.
Topics: Androstenes; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cytochrome P-450 Enzyme System; Humans; Inhibitor of Apoptosis Proteins; Male; Prostate; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Survivin; Transforming Growth Factor beta | 2016 |
Treatment: When less is more.
Topics: Androstenes; Benzamides; Castration; Clinical Trials as Topic; Disease Progression; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Precision Medicine; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone | 2015 |
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.
Topics: Adverse Drug Reaction Reporting Systems; Androstenes; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Humans; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Survival Rate; Thyroid Neoplasms | 2016 |
Commentary on "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer." Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Pa
Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Urology | 2016 |
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Anilides; Animals; Benzamides; Benzimidazoles; Biological Assay; Cell Line; Cricetinae; Dihydrotestosterone; Flutamide; HEK293 Cells; Humans; Male; Microscopy, Fluorescence; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription Factors; Two-Hybrid System Techniques | 2017 |
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Abiraterone Acetate; Administration, Oral; Androgen Antagonists; Androgens; Androstenes; Animals; Cell Line, Tumor; Disease Progression; Dutasteride; Humans; Male; Mice; Oxidation-Reduction; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Xenograft Model Antitumor Assays | 2016 |
Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Quality of Life; Receptors, Estrogen; Survival Rate; Tamoxifen | 2016 |
Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Biomarkers; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome | 2016 |
Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
Topics: Adrenal Glands; Androgens; Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Cell Line; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Naphthalenes; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2016 |
Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Topics: Androstenes; Catalytic Domain; Cell Line, Tumor; Cell Survival; Chromatography, Liquid; Crystallography, X-Ray; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Male; Mass Spectrometry; Molecular Docking Simulation; Nitrogen; Prostate; Prostatic Neoplasms; Protein Binding; Steroid 17-alpha-Hydroxylase; Steroids | 2016 |
Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
Topics: Androstenes; Antineoplastic Agents; Hedgehog Proteins; Humans; Male; Models, Molecular; Molecular Conformation; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2016 |
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Topics: Androstenes; Anilides; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds | 2016 |
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Topics: Adenocarcinoma; Androgens; Androstenes; Animals; Antineoplastic Agents, Phytogenic; Benzamides; Biological Transport; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterografts; Humans; Male; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Organic Anion Transporters, Sodium-Independent; Phenylthiohydantoin; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2016 |
Dihydrotestosterone synthesis pathways from inactive androgen 5α-androstane-3β,17β-diol in prostate cancer cells: Inhibition of intratumoural 3β-hydroxysteroid dehydrogenase activities by abiraterone.
Topics: 3-Hydroxysteroid Dehydrogenases; Androstane-3,17-diol; Androstenes; Cell Line, Tumor; Dihydrotestosterone; Enzyme Inhibitors; Humans; Male; Neoplasm Proteins; Prostatic Neoplasms | 2016 |
[Splicing variant of androgen receptors (AR-V7): New paradigms].
Topics: Alternative Splicing; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Genetic Variation; Humans; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Taxoids | 2016 |
Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy.
Topics: Androstenes; Animals; Apoptosis; Cell Movement; Cell Proliferation; Drug Delivery Systems; Flow Cytometry; Fluorescent Dyes; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Optical Imaging; Prostatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Re: Redirecting Abiraterone Metabolism to Fine-Tune Prostate Cancer Anti-Androgen Therapy.
Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2016 |
Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxyprostaglandin Dehydrogenases; Male; Mice; Neoplasm Staging; Prostatic Neoplasms; Receptors, Androgen; Transcription, Genetic; Xenograft Model Antitumor Assays | 2017 |
Prostate-specific Antigen Response and Eradication of Androgen Receptor Amplification with High-dose Testosterone in Prostate Cancer.
Topics: Adenocarcinoma; Aged; Androstenes; Antineoplastic Agents, Hormonal; Drug Resistance, Neoplasm; Gene Amplification; Humans; Kallikreins; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptors, Androgen; Steroid Synthesis Inhibitors; Testosterone; Treatment Outcome | 2017 |
Prostate cancer: moving forward by reinventing the wheel...but this time it is round.
Topics: Androstenes; Androstenols; Castration; Clinical Trials as Topic; Disease Progression; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms | 2008 |
Cancer expert doubts claims about prostate cancer trial.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Humans; Male; Prostatic Neoplasms | 2008 |
New prostate cancer drug: Prostate cancer's day in the sun.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Male; Prostatic Neoplasms | 2008 |
Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
Topics: Androstenes; Androstenols; Clinical Trials, Phase I as Topic; Humans; Male; Maximum Tolerated Dose; Orchiectomy; Prostatic Neoplasms | 2009 |
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antigens, Neoplasm; Cell Adhesion Molecules; Epithelial Cell Adhesion Molecule; Gene Order; Humans; Immunomagnetic Separation; In Situ Hybridization, Fluorescence; Keratins; Male; Neoplasms, Hormone-Dependent; Neoplastic Cells, Circulating; Oncogene Proteins, Fusion; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Trans-Activators; Transcriptional Regulator ERG | 2009 |
Steroid hormone receptors in prostate cancer: a hard habit to break?
Topics: Androgens; Androstenes; Androstenols; Benzamides; Disease Progression; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Receptors, Estrogen; Signal Transduction | 2009 |
[New drugs in metastatic castration-resistant prostate cancer].
Topics: Androgen Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Castration; Denosumab; Epothilones; ErbB Receptors; Furans; Humans; Immunotherapy; Ketones; Male; Orchiectomy; Prostatic Neoplasms; Pyrrolidines; RANK Ligand | 2010 |
Abiraterone acetate is well tolerated without concomitant use of corticosteroids.
Topics: Adrenal Cortex Hormones; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Orchiectomy; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2010 |
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2011 |
Castration refractory prostate cancer: cinderella finally comes to the ball.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Testosterone; Tissue Extracts | 2010 |
Use of abiraterone for prostate cancer.
Topics: Androstenes; Androstenols; Humans; Male; Prostatic Neoplasms | 2011 |
Abiraterone and MVD3100 take androgen deprivation to a new level.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus; Dihydrotestosterone; Drug Approval; Gonadotropin-Releasing Hormone; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Testosterone; Time Factors; United States; United States Food and Drug Administration | 2011 |
Optimal management of bone metastases in prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Humans; Male; Prostatic Neoplasms; RANK Ligand; Taxoids; Tissue Extracts | 2011 |
New findings in bladder and prostate cancer: highlights from the 26th annual congress of the European Association of Urology, March 18-22, 2011, Vienna, Austria.
Topics: Androstenes; Androstenols; Biomarkers; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Pelvis; Prostatectomy; Prostatic Neoplasms; Radioimmunotherapy; Urinary Bladder Neoplasms | 2011 |
FDA approves prostate cancer treatment that inhibits testosterone synthesis.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Drug Approval; Humans; Male; Prednisone; Prostatic Neoplasms; Testosterone; United States; United States Food and Drug Administration | 2011 |
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Cancer Vaccines; Clinical Trials, Phase III as Topic; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Taxoids | 2011 |
Expanding treatment options for metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase | 2011 |
Prostate cancer: score one for validated targets.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Drug Approval; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms | 2011 |
Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
Topics: Androstadienes; Androstenes; Androstenols; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase III as Topic; Drug Combinations; Estradiol; Humans; Male; Mice; Mice, SCID; Norethindrone; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Testosterone; Xenograft Model Antitumor Assays | 2011 |
Abiraterone acetate.
Topics: Androstenes; Androstenols; Drug Discovery; Humans; Male; Prostatic Neoplasms | 2011 |
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Topics: Alternative Splicing; Androgens; Androstenes; Androstenols; Animals; Biosynthetic Pathways; Cell Proliferation; Dihydrotestosterone; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Xenograft Model Antitumor Assays | 2011 |
Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Costs; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2011 |
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Adrenocorticotropic Hormone; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2011 |
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Topics: Androstenedione; Androstenes; Androstenols; Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Line, Tumor; Dehydroepiandrosterone; Female; Humans; Indomethacin; Male; Mice; Orchiectomy; Pregnenolone; Progesterone; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Up-Regulation | 2011 |
New treatment options for patients with metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
Emerging treatments for castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; Epothilones; Humans; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Tubulin Modulators | 2011 |
Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Substitution; Androstadienes; Androstenes; Androstenols; Benzimidazoles; Cell Cycle Proteins; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Male; Mutation, Missense; Phosphoproteins; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Steroid 17-alpha-Hydroxylase | 2012 |
Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.
Topics: Androstenes; Androstenols; Bone Neoplasms; Histone Deacetylase Inhibitors; Humans; Male; Prostatic Neoplasms; Receptors, Androgen | 2012 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
Topics: Androstadienes; Androstenes; Androstenols; Antineoplastic Agents; Benzimidazoles; Biocatalysis; Catalytic Domain; Crystallography, X-Ray; Humans; Hydrogen Bonding; Ligands; Male; Models, Molecular; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; United States; United States Food and Drug Administration | 2012 |
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Topics: Aged; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Compassionate Use Trials; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2012 |
Abiraterone: current and future use in prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Contraindications; Drug Approval; Enzyme Inhibitors; Humans; Male; Prostatic Neoplasms | 2012 |
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Anilides; Benzamides; Binding, Competitive; Cell Line, Tumor; Drug Interactions; Eplerenone; Humans; Male; Metribolone; Nitriles; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms; Receptors, Androgen; Spironolactone; Tosyl Compounds | 2012 |
Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Attitude of Health Personnel; Benzamides; Bevacizumab; Forecasting; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Practice Patterns, Physicians'; Prostatic Neoplasms; Pyrrolidines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Surveys and Questionnaires; Taxoids; Therapies, Investigational; Thionucleotides; Tissue Extracts; Urology | 2012 |
NICE recommends abiraterone for prostate cancer after manufacturer reduces price.
Topics: Androstenes; Androstenols; Drug Costs; England; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms; Quality of Life; State Medicine; Terminal Care; Wales | 2012 |
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Animals; Benzamides; Castration; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Mice; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Protein Isoforms; Protein Structure, Tertiary; Receptors, Androgen; Signal Transduction; Transcription, Genetic; Transplantation, Heterologous; Ubiquitin-Conjugating Enzymes | 2012 |
Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Topics: Androstenes; Androstenols; Drug Interactions; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms | 2012 |
Importance of food effects for oral oncology drugs.
Topics: Administration, Oral; Androstenes; Androstenols; Antineoplastic Agents; Biological Availability; Eating; Female; Food; Humans; Male; Neoplasms; Orchiectomy; Prostatic Neoplasms | 2012 |
Novel and bone-targeted agents for CRPC.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Ipilimumab; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts; Tumor Microenvironment | 2012 |
NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Castration; Cost-Benefit Analysis; Docetaxel; Drug Costs; Evidence-Based Medicine; Humans; Male; Practice Guidelines as Topic; Prednisolone; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Terminal Care; Time Factors; Treatment Outcome; United Kingdom | 2012 |
Prostate cancer-from steroid transformations to clinical translation.
Topics: Androgen Antagonists; Androstenes; Androstenols; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms | 2012 |
Durable complete remission with abiraterone in castration resistant metastatic prostate cancer.
Topics: Adenocarcinoma; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Castration; Humans; Lymphatic Metastasis; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction | 2013 |
Abiraterone and its place in the treatment of metastatic CRPC.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
New prostate cancer drugs hold promise.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Approval; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Tissue Extracts; United States | 2013 |
Abiraterone. Cougar Biotechnology.
Topics: Androgen Antagonists; Androstenes; Androstenols; Animals; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Licensure; Male; Molecular Structure; NADPH-Ferrihemoprotein Reductase; Patents as Topic; Prostatic Neoplasms; Treatment Outcome | 2006 |